Neuphoria Therapeutics Price Chart
Neuphoria Therapeutics Volume Chart
Neuphoria Therapeutics Market Segments
Regular Trading Hours
-0.02(-0.38%)
| Open | $5.30 |
|---|---|
| Close | $5.28 |
| Low | $5.22 |
| Low Change | -0.08 (-1.51%) |
| High | $5.33 |
| High Change | +0.03 (+0.47%) |
| Range | $0.11 |
| Volume | 8.372K |
| Dollar Volume | $44.20K |
Premarket
-0.01(-0.19%)
| Open | $5.24 |
|---|---|
| Close | $5.23 |
| Low | $5.23 |
| Low Change | -0.01 (-0.19%) |
| High | $5.24 |
| High Change | +0.00 (+0.00%) |
| Range | $0.01 |
| Volume | 1.607K |
| Dollar Volume | $8.40K |
After Hours Yesterday
*No Trades in Segment
Regular Trading Hours Yesterday
+0.07(+1.35%)
| Open | $5.20 |
|---|---|
| Close | $5.27 |
| Low | $5.19 |
| Low Change | -0.01 (-0.16%) |
| High | $5.37 |
| High Change | +0.17 (+3.27%) |
| Range | $0.18 |
| Volume | 27.227K |
| Dollar Volume | $143.49K |
Premarket Yesterday
-0.07(-1.33%)
| Open | $5.26 |
|---|---|
| Close | $5.19 |
| Low | $5.19 |
| Low Change | -0.07 (-1.33%) |
| High | $5.26 |
| High Change | +0.00 (+0.00%) |
| Range | $0.07 |
| Volume | 720 |
| Dollar Volume | $3.74K |
Neuphoria Therapeutics Moving Averages
| 5 Day Moving Average (SMA5) | $5.17 |
|---|---|
| 10 Day Moving Average (SMA10) | $5.05 |
| 20 Day Moving Average (SMA20) | $4.83 |
| 50 Day Moving Average (SMA50) | $4.59 |
| 100 Day Moving Average (SMA100) | $4.31 |
| 200 Day Moving Average (SMA200) | $6.58 |
Neuphoria Therapeutics Statistics
| Average Volume (30 Days) | — |
|---|---|
| P/E Ratio (Current) | — |
| EPS (Current) | — |
| Dividend Yield | — |
| Free Cash Flow | — |
| Cash Ratio | — |
| Current Ratio | — |
| Quick Ratio | — |
| Debt to Equity | — |
| Enterprise Value | — |
| EV to EBITDA | — |
| EV to Sales | — |
| Price to Book | — |
| Price to Cash Flow | — |
| Price to Free Cash Flow | — |
| Price to Sales | — |
| Return on Assets | — |
| Return on Equity | — |
Neuphoria Therapeutics Stock Splits
There have been no stock splits for Neuphoria Therapeutics (NEUP).
Neuphoria Therapeutics Dividends
There have been no dividends for Neuphoria Therapeutics (NEUP).